Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens

NCT ID: NCT01706770

Last Updated: 2020-10-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of thes study is to confirm that the ocular response to the Test lenses are similar to those of the Control lenses when used in a 1 week planned replacement, daily wear modality over a 1-month period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The test lens and control lens were randomized in a 2:1 ratio to evaluate the test lens and control contact lens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ametropia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

enfilcon A

The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.

Group Type EXPERIMENTAL

enfilcon A

Intervention Type DEVICE

galyfilcon A

The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.

Group Type ACTIVE_COMPARATOR

galyfilcon A

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

enfilcon A

Intervention Type DEVICE

galyfilcon A

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Avaira® Toric Acvuve® Advance®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Prior to being considered eligible to participate in this study, each subject MUST:

* Be at least 18 years of age as of the date of evaluation for the study.
* Have read the Informed Consent, been given an explanation of the Informed Consent, indicated understanding of the Informed Consent, signed the Informed Consent document.
* Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
* Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses in both eyes on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
* Possess wearable and visually functional eyeglasses.
* Be in good general health, based on his/her knowledge.
* Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 2.00 diopters of refractive astigmatism and be willing to wear contact lenses in both eyes.
* Have: manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
* Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.


To be eligible for lens dispensing (either Test or Control), the subject's study lens contact lens visual acuity must be equal to or better than 20/30 in each eye.

Exclusion Criteria

Subjects may not be enrolled in this study if any of the following apply: The subject is/has:

* Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
* Poor personal hygiene.
* Any active participation in another clinical trial within 30 days prior to this study.
* Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the study period.
* A member, relative or household member of the investigator or of the investigational office staff.
* Has a known sensitivity to ingredients used in the care products approved for use in the study.
* Previous refractive surgery; or current or previous orthokeratology treatment.
* Is aphakic or psuedophakic.
* Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
* The need for topical ocular medications or any medication which might interfere with contact lens wear or which would require the lenses to be removed during the day.
* The presence of clinically significant (grade 3 or 4) anterior segment abnormalities.
* Any; inflammations such as iritis; or any infection or allergic reaction of the eye, lids, or associated structures.
* A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates or fungal infections.
* A history of papillary conjunctivitis that has interfered with contact lens wear.
* Slit lamp findings that would contraindicate contact lens wear, including but not limited to: Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2, Pterygium, Corneal scars within the visual axis, Neovascularization or ghost vessels \> 1.0 mm in from the limbus, Giant papillary conjunctivitis (GPC) of \> Grade 1, Anterior uveitis or iritis, Seborrheic eczema, seborrheic conjunctivitis or blepharitis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CooperVision, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Scott E Schachter, OD

Role: PRINCIPAL_INVESTIGATOR

Unafiliated

Cheryl Vincent-Reimer, OD

Role: PRINCIPAL_INVESTIGATOR

Unafiliated

Eric White, OD

Role: PRINCIPAL_INVESTIGATOR

Unafiliated

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Advanced Eyecare

Pismo Beach, California, United States

Site Status

Eric M. White, OD, Inc.

San Diego, California, United States

Site Status

Vision Care Associates

East Lansing, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FC111216

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.